Vertex pharmaceuticals inc
VRTX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
VRTX 近期報酬表現
-0.76%
Vertex pharmaceuticals inc
0.54%
同產業平均
-0.46%
S&P500
與 VRTX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
INCY | Incyte corp | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
SGMT | Sagimet biosciences inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
CCCC | C4 therapeutics inc | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
JNJ | Johnson & johnson | 2 分 | 2 分 | 1 分 | 3 分 | 5 分 | |
AMGN | Amgen inc | 3 分 | 1 分 | 2 分 | 3 分 | 5 分 |
- INCY Incyte corp價值 3 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
VRTX 公司資訊
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.